Could You Patent the Sun? The Story Behind Jonas Salk's Decision to Forgo the Polio Vaccine Patent

On the evening of April 12, 1955, sitting under studio lights across from Edward R. Murrow on See It Now, Jonas Salk was asked a simple question about the polio vaccine he had just spent seven years developing: Who owned the patent? According to widely reported accounts, Salk responded that there was no patent and asked rhetorically whether one could patent the sun. The exchange, verified in accounts of the broadcast, went out live to a country that had, that same day, been told the shot was safe and effective against paralytic polio.

The decision cost Salk an estimated seven billion dollars in forgone personal wealth. He never seemed to mind. Within a decade, vast numbers of children had rolled up their sleeves for a vaccine whose formula was essentially open source.

The Disease That Terrified a Nation

To understand the shape of that answer, one must understand what polio was doing to American childhood. In 1952 alone, around 58,000 American children contracted polio. More than 21,000 were paralyzed and 3,000 died. The disease would start like a cold, and then, all of a sudden, children could not breathe or could not move their arms and legs. Because polio epidemics happened sporadically, parents never knew when the next one would take place.

Iron lungs lined hospital wards. Public swimming pools emptied every summer. Parents kept children indoors in August. The virus spreads through the fecal-oral route and has no cure — treatment meant managing symptoms and hoping the paralysis did not reach the muscles that pull air into the lungs.

The Science Behind the Vaccine

Salk, working at the University of Pittsburgh查看公司主页 School of Medicine, began his vaccine research in the late 1940s. His path was set years earlier, during a microbiology class at New York University College of Medicine, when a professor told students it was not possible to protect the body against viral diseases using an inactivated virus. That lecture set Salk on a course to challenge this longstanding dogma.

While still in medical school, Salk began working with Thomas Francis Jr. on methods to inactivate influenza viruses. The team developed the first successful influenza vaccine, using chemically inactivated influenza viruses, introduced to the military and then the general public in 1946. In 1947, Salk started his own lab at the University of Pittsburgh查看公司主页, gathering a strong team to work toward a polio vaccine.

A pall had been cast over such programs in the 1930s, when two attempts to create a polio vaccine failed to produce immunity — one actually caused polio in a small number of subjects. Salk's team knew they had to take a more systematic approach. They used a new method, developed by scientists at Harvard, of growing polioviruses in laboratory cultures of monkey cells bathed in a nutrient medium. The team could then determine the exact combinations of heat and formaldehyde solution required to kill the viruses reliably without altering the virus's structure so much that the immune response would no longer match the original virus.

Two members of the team, Elsie Ward and Julius Youngner, devised a clever method using a pH indicator dye to quickly establish whether live polioviruses were still present in test samples. Animal cells growing in test tubes would naturally turn the medium more acidic over time, changing its color from red to yellow. If live poliovirus was present, the virus would kill the cells and the medium would remain red. This at-a-glance method significantly accelerated vaccine production and testing.

By the early 1950s, Salk had an experimental trivalent solution targeting all three known strains of the virus. He tested it first on himself, his wife, and his three sons. Peter Salk, then 9 years old, later recalled the moment: "My father brought some vaccine home and sterilized the syringes and needles by boiling them on the stove. Then he lined us up." Remarkably, Peter remembered, "when my father inserted the needle this time, I didn't feel it. I've never forgotten that moment, standing in the kitchen, seeing the sunlight coming in through the window and realizing that my fears had been unnecessary."

The Largest Medical Field Trial in History

The 1954 field trial was not a small operation. Approximately 1.8 million American schoolchildren across dozens of states — the "Polio Pioneers" — participated. One branch of the study was double-blind: half the children received the vaccine while the other half received a placebo injection, and neither the doctors nor the families knew which group the children were in. In another branch, second graders got the vaccine with parental approval, while first and third graders at the same schools remained unvaccinated and served as observed controls.

The money for all of this did not come from a pharmaceutical company. It came from dimes. The National Foundation for Infantile Paralysis — the organization the country would come to know as the March of Dimes — collected donations from tens of millions of Americans. Walt Disney's cartoon characters recorded anti-polio songs. Schools ran coin drives. By the time Murrow asked his question, the public had already, in a very literal sense, paid for the vaccine. Patenting it for profit would have amounted to charging them twice.

On April 12, 1955, Thomas Francis, Salk's earlier mentor who was responsible for evaluating the data, announced the results: the new vaccine was "safe, effective and potent" against all three strains of polio. Doctors watched the press conference on closed-circuit TV. Church bells rang out. Workplaces observed moments of silence or celebration. The press event drew a bigger radio audience than most presidential addresses of the era.

The Reality Behind the Patent Question

The sentence itself has become one of the most quoted moments in the history of American science. It has been carved onto plaques, printed on posters, and repeated by every generation of medical students since.

The reality behind the line is more textured than the myth. Lawyers for the National Foundation for Infantile Paralysis had in fact looked into a patent application before the interview, according to documents unearthed by Jane Smith, author of Patenting the Sun: Polio and the Salk Vaccine. They concluded the vaccine would not clear the novelty bar required by U.S. patent law. There was no patent partly because Salk and his backers did not want one, and partly because the lawyers were not sure they could get one. The foundation had also already handed the formulation and manufacturing processes to several pharmaceutical companies at no cost.

What the Decision Made Possible

Because the formulation was freely shared, foreign governments could license production almost immediately. The Soviet Union manufactured its own supply. So did Canada, the United Kingdom, Denmark, and dozens of other countries. By the early 1960s, when Albert Sabin's oral vaccine began to supplement the Salk injection, hundreds of millions of children had received one shot or the other. Within seven years of the 1955 announcement, enough children were inoculated that the incidence of polio in the United States dropped by 97 percent.

India tells the story in miniature. In the late 1970s, the Indian government began mass polio vaccination under a national program. The Universal Immunization Program, launched in the mid-1980s, pushed coverage to high levels. Reported cases fell dramatically from the late 1980s through the mid-1990s. The Pulse Polio Program, launched in the mid-1990s, drove the numbers toward zero. The last wild polio cases in India were recorded in West Bengal and Gujarat in early 2011. On March 27, 2014, the World Health Organization declared India polio-free — a country with hundreds of millions of children, cleared of a virus that had crippled generations.

Global wild poliovirus cases have fallen more than 99 percent since 1988, when the Global Polio Eradication Initiative launched. Only two countries — Afghanistan and Pakistan — still report endemic transmission of wild type 1. The Salk inactivated vaccine, updated but recognizably the same design, remains part of the routine childhood schedule in most of the world.

The Critique and the Legacy

Salk's answer has aged into something like scripture for critics of pharmaceutical pricing. It came up during the AIDS crisis, during the Hepatitis C sofosbuvir debate, and again during the COVID-19 vaccine rollout, when governments argued over waiving intellectual property protections on mRNA shots.

Salk's own position turned out to be less absolute than the quote suggests. Near the end of his life he helped found a company to develop an HIV vaccine, and that company filed patent applications on the early candidates. The vaccine failed in trials, but the paperwork was real. The man who had asked whether you could patent the sun understood, by the 1990s, that the machinery of modern drug development ran on financial incentives.

What made 1955 different was that the polio vaccine had been built almost entirely outside that machinery. A nonprofit had funded the research. Millions of ordinary donors had paid for the trials. Universities had done the science. There was no venture capital to reward, no shareholder to answer to, no board demanding a return.

At a March of Dimes commemoration, Salk's son Peter noted that the world was approaching complete eradication of the polio virus. The vaccine went into hundreds of millions of arms. The dimes had done their work.